Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;33(10):108.
doi: 10.1007/s12032-016-0821-1. Epub 2016 Aug 29.

Hypofractionation with no boost after breast conservation in early-stage breast cancer patients

Affiliations

Hypofractionation with no boost after breast conservation in early-stage breast cancer patients

Francesca Arcadipane et al. Med Oncol. 2016 Oct.

Abstract

The aim of this study was to evaluate local control, survival and toxicity profile of a consecutive cohort of early-stage breast cancer (EBC) patients treated with adjuvant hypofractionated radiotherapy (HF) with no boost delivered to the lumpectomy cavity, after breast-conserving surgery (BCS). Between 2005 and 2015, a total of 493 women affected with EBC were treated with HF (46 Gy/20 fractions or 40.05 Gy/15 fractions) to the whole breast without boost to tumor bed, because of age and/or favorable tumor characteristics. The primary endpoint was 5-year actuarial local control (LC); secondary endpoints included survival, toxicity profile and cosmesis. Median follow-up was 57 months (range 6-124). Actuarial 5-year overall, cancer-specific, disease-free survival and LC were 96.3, 98.9, 97.8 and 98.6 %, respectively. On multivariate analysis, tumor stage (T1 vs. T2) and hormonal status (positive vs. negative estrogen receptors) were significantly correlated with LC. Only 2 % of patients experienced ≥G3 acute skin toxicity. Late toxicity was mild with only 1 case of G3 fibrosis. Most of the patients (95 %) had good-excellent cosmetic results. HF to the whole breast with no boost delivered to the tumor bed is a safe and effective option for a population of low-risk breast cancer patients after BCS, with excellent 5-year LC, mild toxicity profile and promising cosmetic outcome. A subgroup of patients with larger tumors and/or with no estrogen receptor expression may potentially benefit from treatment intensification with a boost dose to the lumpectomy cavity.

Keywords: Adjuvant therapy; Boost; Breast cancer; Hypofractionated radiotherapy; Hypofractionation; Local control.

PubMed Disclaimer

References

    1. Radiother Oncol. 2011 Jul;100(1):101-7 - PubMed
    1. J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50 - PubMed
    1. J Cancer Res Clin Oncol. 2013 Nov;139(11):1927-36 - PubMed
    1. Lancet Oncol. 2013 Oct;14(11):1086-94 - PubMed
    1. Eur J Cancer. 2009 Mar;45(5):730-1 - PubMed

LinkOut - more resources